Relapsed biliary tract cancer, and ASCO, beckon.
ApexOnco Front Page
Recent articles
The phase 2/3 Revival trial will test a ven/aza combo in first-line AML.
Full US approval of Gilead’s Tecartus was the only positive decision last month.
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
The two companies have been involved in recent licensing deals.
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
MK-6837 has been discontinued, the company discloses.
The company discontinues the Lag3 project in lung cancer.
